A Quality Tax for Foreign Drug Makers? The Links Between National Security, Trade Deals, and Drug Quality. February 2, 2026 By John W.M. Claud & Mark I. Schwartz —

https://www.thefdalawblog.com/2026/02/a-quality-tax-for-foreign-drug-makers-the-links-between-national-security-trade-deals-and-drug-quality/?utm_source=rss&utm_medium=rss&utm_campaign=a-quality-tax-for-foreign-drug-makers-the-links-between-national-security-trade-deals-and-drug-quality Over the past year, FDA has placed pressure on foreign drugmakers to bring their manufacturing into the U.S. FDA Commissioner Marty Makary posted his Top 10 accomplishments recently, and promoting domestic production was among them. This followed similar remarks at the 2026 J.P. Morgan Healthcare Conference. FDA’s regulatory policies here are in service of a merger of drug quality, international trade, and national security to address concerns that foreign drug manufacturing poses threats to American consumers.